Status:
COMPLETED
Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty
Lead Sponsor:
Centre Hospitalier de Montauban
Conditions:
Postoperative Hemorrhage
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Tranexamic acid an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin and many studies confirms its effectiveness in decreasing blood loss. Th...
Detailed Description
Total knee arthroplasty (TKA) is widely used as an effective treatment for end-stage osteoarthritis and other joint diseases of the knee and it improvements in surgical materials and techniques have g...
Eligibility Criteria
Inclusion
- \- Adult patients undergoing unilateral total knee replacement
Exclusion
- Absence of consent
- Tranexamic acid allergy
- Coagulopathy (preoperative platelet count \<150,000 / mm3, INR \[international normalized ratio\]\> 1.4, or prolonged partial thromboplastin time\> 1.4 times normal),
- History of arterial or venous thromboembolic disease (cerebrovascular accident, deep vein thrombosis or pulmonary thromboembolism),
- Hematological disorder (a hematopoietic, hemorrhagic or thrombogenic disease),
- Retinopathy (severe limitation of the field of vision and / or color distortion),
- Refusal to receive blood products
- Pregnancy
- History of convulsions
- Participation in another clinical trial.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 9 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04085575
Start Date
January 1 2019
End Date
January 9 2020
Last Update
July 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Edmundo Pereira de Souza Neto
Montauban, Tarn Et Garonne, France, 82000